VINC - Vincerx Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Palo Alto,
United States
Type: Equity
VINC price evolution
VINC
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8.01 | $5.19 | $12.85 | $15.15 |
| Short term investments | $8.4 | $5.72 | ||
| Net receivables | $2.35 | $2.23 | $1.04 | $1.05 |
| Inventory | ||||
| Total current assets | $18.28 | $7.68 | $14.73 | $22.82 |
| Long term investments | ||||
| Property, plant & equipment | $1.79 | $2.06 | $2.33 | $2.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.24 | $3.41 | $3.48 | $3.46 |
| Total investments | $8.4 | $5.72 | ||
| Total assets | $21.53 | $11.08 | $18.22 | $26.28 |
| Current liabilities | ||||
| Accounts payable | $1.54 | $2.31 | $2.5 | $3.06 |
| Deferred revenue | ||||
| Short long term debt | $1.24 | $1.2 | $1.16 | $1.13 |
| Total current liabilities | $5.33 | $10.63 | $5.61 | $8.85 |
| Long term debt | $0.7 | $1.02 | $1.34 | $1.64 |
| Total noncurrent liabilities | $0.75 | $1.07 | $1.39 | $1.69 |
| Total debt | $1.93 | $2.22 | $2.5 | $2.77 |
| Total liabilities | $6.08 | $11.71 | $7 | $10.54 |
| Shareholders' equity | ||||
| Retained earnings | -$173.35 | -$171.54 | -$159.11 | -$156.54 |
| Other shareholder equity | $0.02 | $0.06 | $0.01 | $0.05 |
| Total shareholder equity | $15.45 | -$0.62 | $11.22 | $15.74 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.85 | $11.73 | $111.56 | $61.79 |
| Short term investments | $40.8 | |||
| Net receivables | $1.04 | $1.37 | ||
| Inventory | ||||
| Total current assets | $14.73 | $55.96 | $111.84 | $63.11 |
| Long term investments | ||||
| Property, plant & equipment | $2.33 | $3.24 | $4.18 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.48 | $3.32 | $5.83 | $0.08 |
| Total investments | $40.8 | |||
| Total assets | $18.22 | $59.29 | $117.68 | $63.19 |
| Current liabilities | ||||
| Accounts payable | $2.5 | $3.06 | $2.02 | $5.5 |
| Deferred revenue | ||||
| Short long term debt | $1.16 | $1.02 | $0.74 | |
| Total current liabilities | $5.61 | $9.16 | $13.92 | $37.81 |
| Long term debt | $1.34 | $2.41 | $3.44 | |
| Total noncurrent liabilities | $1.39 | $2.46 | $3.44 | |
| Total debt | $2.5 | $3.44 | $4.17 | |
| Total liabilities | $7 | $11.62 | $17.36 | $37.81 |
| Shareholders' equity | ||||
| Retained earnings | -$159.11 | -$121.34 | -$55.97 | -$16.66 |
| Other shareholder equity | $0.01 | -$0.03 | -$0.02 | |
| Total shareholder equity | $11.22 | $47.67 | $100.32 | $25.38 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $3.75 | $4.56 | $3.71 | $6.8 |
| Selling, general & administrative | $3.61 | $2.92 | $1.82 | $3.52 |
| Total operating expenses | $7.37 | $7.48 | $5.53 | $10.32 |
| Operating income | -$7.37 | -$7.48 | -$5.53 | -$10.32 |
| Income from continuing operations | ||||
| EBIT | -$1.81 | -$12.43 | -$4.95 | -$9.71 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1.81 | -$12.43 | -$4.95 | -$9.71 |
| Income (for common shares) | -$1.81 | -$12.43 | -$4.95 | -$9.71 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $28.97 | $52.15 | $40.08 | $7.12 |
| Selling, general & administrative | $13.64 | $18.95 | $22.57 | $3.6 |
| Total operating expenses | $42.61 | $73.57 | $62.66 | $10.71 |
| Operating income | -$42.61 | -$73.57 | -$62.66 | -$10.71 |
| Income from continuing operations | ||||
| EBIT | -$40.16 | -$65.37 | -$39.31 | -$16.61 |
| Income tax expense | ||||
| Interest expense | $0.01 | |||
| Net income | ||||
| Net income | -$40.16 | -$65.37 | -$39.31 | -$16.62 |
| Income (for common shares) | -$40.16 | -$65.37 | -$39.31 | -$16.62 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$1.81 | -$12.43 | -$4.95 | -$9.71 |
| Operating activities | ||||
| Depreciation | $0.27 | $0.26 | $0.26 | $0.25 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.91 | $0.53 | $0.46 | $1.34 |
| Total cash flows from operations | -$5.83 | -$7.74 | -$8.02 | -$6.64 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$8.34 | $5.75 | $15.06 | |
| Total cash flows from investing | -$8.34 | $5.75 | $15.06 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17 | $0.01 | $0.02 | |
| Net borrowings | ||||
| Total cash flows from financing | $17 | $0.01 | $0.02 | |
| Effect of exchange rate | -$0.02 | $0.07 | -$0.04 | -$0.02 |
| Change in cash and equivalents | $2.81 | -$7.66 | -$2.29 | $8.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$40.16 | -$65.37 | -$39.31 | -$16.62 |
| Operating activities | ||||
| Depreciation | $0.92 | $0.94 | $0.34 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.56 | $12.44 | $23.31 | $4.38 |
| Total cash flows from operations | -$40.45 | -$59.6 | -$33.4 | -$2.28 |
| Investing activities | ||||
| Capital expenditures | -$5.26 | |||
| Investments | $41.5 | -$40.58 | ||
| Total cash flows from investing | $41.5 | -$40.58 | -$5.26 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.11 | $0.28 | $88.45 | $64.07 |
| Net borrowings | ||||
| Total cash flows from financing | $0.11 | $0.28 | $88.45 | $64.07 |
| Effect of exchange rate | -$0.04 | $0.07 | -$0.02 | |
| Change in cash and equivalents | $1.12 | -$99.83 | $49.77 | $61.79 |
News
Fundamentals
| Market cap | $11.22M |
|---|---|
| Enterprise value | $5.14M |
| Shares outstanding | 29.67M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$27.86M |
| EBIT | -$28.90M |
| Net Income | -$28.90M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.39 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.18 |
| EV/EBIT | -0.18 |
| P/S ratio | N/A |
| P/B ratio | 0.73 |
| Book/Share | 0.52 |
| Cash/Share | 0.27 |
| EPS | -$0.97 |
|---|---|
| ROA | -149.94% |
| ROE | -276.65% |
| Debt/Equity | 0.62 |
|---|---|
| Net debt/EBITDA | 0.07 |
| Current ratio | 3.43 |
| Quick ratio | 3.43 |